Long-term efficacy and safety of ocrelizumab in treatment-naive patients with early relapsing multiple sclerosis: 7-year data from the OPERA open-label extension trials

被引：0
作者：
Cerqueira, J. [1 ]
Berthele, A. [2 ]
Cree, B. [3 ]
Filippi, M. [4 ,5 ,6 ,7 ,8 ]
Pardo, G. [9 ]
Pearson, O. [10 ]
Trabloulsee, A. [11 ]
Ziemssen, T. [12 ]
Vollmer, T. [13 ]
Bernasconi, C. [14 ]
Mandel, C. [15 ]
Overell, J. [14 ]
Havrdova, E. [16 ,17 ,18 ]
机构：
[1] Univ Minho, Life & Hlth Sci Res Inst, Sch Med, Braga, Portugal
[2] Tech Univ Munich, Sch Med, Dept Neurol, Munich, Germany
[3] Univ Calif San Francisco, UCSF Weill Inst Neurosci, Dept Neurol, San Francisco, CA USA
[4] IRCCS San Raffaele Sci Inst, Div Neurosci, Neuroimaging Res Unit, Milan, Italy
[5] IRCCS San Raffaele Sci Inst, Neurol Unit, Milan, Italy
[6] IRCCS San Raffaele Sci Inst, Neurorehabilitat Unit, Milan, Italy
[7] IRCCS San Raffaele Sci Inst, Neurophysiol Serv, Milan, Italy
[8] Univ Vita Salute San Raffaele, Milan, Italy
[9] Oklahoma Med Res Fdn, Multiple Sclerosis Ctr Excellence, Oklahoma City, OK USA
[10] Morriston Hosp, Dept Neurol, Swansea, W Glam, Wales
[11] Univ British Columbia, Dept Neurol, Vancouver, BC, Canada
[12] Tech Univ Dresden, Univ Clin Carl Gustav Carus, Dept Neurol, Ctr Clin Neurosci, Dresden, Germany
[13] Univ Colorado Denver, Dept Neurol, Rocky Mt Multiple Sclerosis Ctr, Anschutz Med Campus, Denver, CO USA
[14] F Hoffmann Roche Ltd, Basel, Switzerland
[15] Genentech Inc, San Francisco, CA USA
[16] Gen Univ Hosp, Prague, Czech Republic
[17] Charles Univ Prague, Dept Neurol, Prague, Czech Republic
[18] Charles Univ Prague, Ctr Clin Neurosci, Prague, Czech Republic
来源：
MULTIPLE SCLEROSIS JOURNAL | 2022年 / 28卷 / 3_SUPPL期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P723
引用
收藏
页码：634 / 635
页数：2
相关论文
共 50 条
  • [31] Safety and Efficacy of Frexalimab in the Treatment of Relapsing Multiple Sclerosis: 18-month Results from the Phase 2 Open-Label Extension
    Giovannoni, Gavin
    Granziera, Cristina
    Mao-Draayer, Yang
    Cutter, Gary
    Kalbus, Oleksandr
    Staikov, Ivan
    Dufek, Michal
    Saubadu, Stephane
    Bejuit, Raphael
    Smyth, Brendan
    Djukic, Biljana
    Truffinet, Philippe
    Wallstroem, Erik
    Vermersch, Patrick
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 64 - 65
  • [32] Safety and Efficacy of Tolebrutinib from the Long-term Extension Study in Relapsing Multiple Sclerosis: 2.5-Year Results
    Oh, J.
    Syed, S.
    Li, T.
    Salloum, N.
    Turner, T.
    Fox, R.
    EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 : 642 - 643
  • [33] Zanaflex® treatment of spasticity in patients with multiple sclerosis:: A long-term, open-label study
    Stazio, A
    Groves, L
    Hudson, S
    NEUROLOGY, 1998, 50 (04) : A147 - A147
  • [34] VISIONARY-MS Long-Term Extension: A Multicenter, Open-Label, Long-Term Extension Study of CNM-Au8 in Patients With Stable Relapsing Multiple Sclerosis
    Barnett, Michael
    Beadnall, Heidi
    Klistorner, Alexander
    Sergott, Robert
    Greenberg, Benjamin
    Rynders, Austin
    Ho, Karen
    Sepassi, Marjan
    Evan, Jacob
    Evan, Jeremy
    McBride, Ryan
    Hartford, Alan
    Hotchkin, Michael
    NEUROLOGY, 2024, 102 (12) : S12 - S13
  • [35] Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study
    Gold, Ralf
    Radue, Ernst-Wilhelm
    Giovannoni, Gavin
    Selmaj, Krzysztof
    Havrdova, Eva
    Stefoski, Dusan
    Sprenger, Till
    Montalban, Xavier
    Cohan, Stanley
    Umans, Kimberly
    Greenberg, Steven J.
    Ozen, Gulden
    Elkins, Jacob
    BMC NEUROLOGY, 2016, 16
  • [36] INTERIM LONG-TERM SAFETY/EFFICACY OF RISANKIZUMAB TREATMENT IN CROHN'S DISEASE PATIENTS FROM THE OPEN-LABEL EXTENSION STUDY
    Ferrante, M.
    Panes, J.
    Baert, F.
    Louis, E.
    Kaser, A.
    Gustafson, D.
    Hall, D.
    Boecher, W. O.
    Herichova, I.
    Liao, X.
    Wallace, K.
    Kalabic, J.
    D'Haens, G.
    GUT, 2019, 68 : A64 - A64
  • [37] Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study
    Ralf Gold
    Ernst-Wilhelm Radue
    Gavin Giovannoni
    Krzysztof Selmaj
    Eva Havrdova
    Dusan Stefoski
    Till Sprenger
    Xavier Montalban
    Stanley Cohan
    Kimberly Umans
    Steven J. Greenberg
    Gulden Ozen
    Jacob Elkins
    BMC Neurology, 16
  • [38] Long-term Efficacy and Safety From an Open-Label Extension of Adjunctive Cenobamate in Patients With Uncontrolled Focal Seizures
    Klein, Pavel
    Aboumatar, Sami
    Brandt, Christian
    Dong, Fang
    Krauss, Gregory L.
    Mizne, Sarah
    Sanchez-Alvarez, Juan Carlos
    Steinhoff, Bernhard J.
    Villanueva, Vicente
    NEUROLOGY, 2022, 99 (10) : E989 - E998
  • [39] Long-term safety and efficacy of add-on cannabidiol for treatment of seizures associated with tuberous sclerosis complex in an open-label extension
    Kwan, Patrick
    Thiele, Elizabeth A.
    Bebin, E. Martina
    Filloux, Francis
    Jansen, Floor E.
    Loftus, Rachael
    Sahebkar, Farhad
    Sparagana, Steven
    Wheless, James
    EPILEPSIA, 2021, 62 : 145 - 146
  • [40] Long-term safety and efficacy of teriflunomide in patients with relapsing forms of multiple sclerosis in the TEMSO extension trial
    Freedman, M.
    Wolinsky, J.
    Comi, G.
    Kappos, L.
    Olsson, T.
    Miller, A.
    Benamor, M.
    Dukovic, D.
    Liang, J.
    Truffinet, P.
    O'Connor, P.
    MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (11) : 225 - 225
12345